Latest News Archive

Please select Category, Year, and then Month to display items

Researchers developing 3D cell culture models to advance drug discovery

11 July 2024 | Story André Damons | Photo supplied

FARMVOS — From top (left to right): Dr Angélique Lewies (researcher from the Robert WM Frater Cardiovascular Research Centre within the UFS Department of Cardiothoracic Surgery), Zurika Murray (behavioural geneticist from the UFS Department of Genetics), Dr Marieka Gryzenhout (C-rated scientist and Senior Lecturer in the Department of Genetics), and Dr Jaco Wentzel (serves as the pharmaceutical industry partner and consultant for the project at FARMOVS).

In an effort to advance drug discovery and disease research, researchers from the University of the Free State (UFS), the Central University of Technology (CUT), and FARMOVS, a clinical research company associated with the UFS, is developing innovative 3D cell culture models using 3D printed mini bioreactors.

This interdisciplinary project, led by Dr Angélique Lewies, researcher from the Robert WM Frater Cardiovascular Research Centre (Frater Centre) within the UFS Department of Cardiothoracic Surgery, is creating more accurate and human-like models for this purpose, reducing the need for animal testing, and improving the safety and effectiveness of new treatments.

The project was initiated to address the challenges associated with current 3D cell culture techniques, which are often expensive and complex. Recognising the need for a more cost-effective and user-friendly solution, the researchers embarked on this collaboration to develop a novel 3D cell culture system. By making these advanced techniques more accessible, the team aims to enhance the reliability of drug testing and significantly reduce the reliance on animal experiments. This innovative approach not only promises to cut costs but also promotes ethical research practices in the scientific community.

Dr Lewies, whose research specialises in cardio-oncology (relationship between cancer treatment and heart health), particularly in understanding and preventing damage to cardiac cells caused by chemotherapy, leads the cell biology aspects of the project, focusing on the cultivation of 3D cancer spheroid and organoid cultures.

According to her, the project focuses on creating 3D cell cultures, known as spheroids and organoids, that mimic human tissues more closely. These 3D models can improve the reliability of drug testing and reduce the need for animal experiments, aligning with the 3R principles: Reduction, Replacement, and Refinement.

Creating a versatile platform

“Traditional drug discovery and disease studies often rely on flat (2D) cell cultures and animal models. While animal models are essential for understanding disease and testing drug safety, they don't always predict how humans will respond, and their use raises ethical concerns.

“We aim to develop affordable and efficient 3D-printed mini bioreactors for growing these advanced cell cultures. These bioreactors will be designed to fit into existing cell culture labs, making them accessible to researchers. By leveraging the cutting-edge 3D printing technology at CUT's Centre for Rapid Prototyping and Manufacturing (CRPM), the team hopes to create a versatile platform for various research applications,” says Dr Lewies.

She is joined in this project by UFS colleagues; Zurika Murray, a behavioural geneticist, and her colleague from the Department of Genetics, Dr Marieka Gryzenhout, a C-rated scientist and Senior Lecturer. Dr Jaco Wentzel from FARMOVS. is also involved in the project. Dr Wentzel serves as the pharmaceutical industry partner and consultant for the project. With experience in cellular biology and pharmaceuticals, he ensures that the new 3D cell culture models meet industry standards and can be effectively used in drug development. Dr Wentzel’s role is crucial in bridging the gap between academic research and practical application in the pharmaceutical industry.

Goals

According to Dr Lewies, this project aims to create more accurate and ethical models for drug testing and improving the development of new treatments. By combining expertise from engineering, biology, and mycology, the team is set to revolutionise how diseases are studied, and medicines developed. Funded by the CUT and UFS Joint Research Programme, this initiative promises to foster innovation and lead to new research collaborations.

“Cardiac cell damage, known as cardiotoxicity, can lead to serious cardiovascular diseases and is a major reason why some drugs are removed from the market. By developing 3D cancer spheroids and cardiac organoids (mini heart models), my team aims to find ways to prevent this cardiotoxicity while enhancing the effectiveness of chemotherapy drugs.

“Additionally, they are exploring the cardiotoxic effects of natural products, such as medicinal plants and mushrooms, which show potential for both anticancer and cardio-protective properties,” says Dr Lewies.

Experts

Murray is interested in how the psychedelic compounds psilocybin and psilocin affect the brain with her research focusing on the epigenome of genes within the serotonin pathway, which could explain the therapeutic potential of these compounds. “As part of this project, Murray will work with the Frater Centre to develop neuronal organoids (mini brain models) using the 3D mini-bioreactor platform.

“This will allow her to investigate the effects of psilocybin and psilocin on brain function, which have shown promise in treating mental health disorders like depression and anxiety, aiming to understand how these substances might help treat mental health issues,” says Dr Lewies.

Dr Gryzenhout brings her expertise in mycology and is responsible for cultivating medicinal mushrooms used in the project. Dr Gryzenhout's research focuses on the genetic characterisation of medicinal mushrooms and evaluating their therapeutic potential. These mushrooms produce a variety of bioactive compounds with therapeutic benefits, including anticancer activities, heart protection, and immune system support.

Her team is also approved by the South African Health Products Regulatory Authority (SAHPRA) to research the controlled psychedelic compounds psilocybin and psilocin.

Drug Discovery Goals

The project’s long-term focus is on potentially discovering new drugs to prevent and treat heart and brain diseases. Specifically, the team is working on developing therapies for cardio-oncology and neurological applications. In the realm of cardio-oncology, the goal is to find treatments that prevent cardiac cell damage and downstream cardiovascular diseases caused by cancer therapies, while still effectively targeting cancer cells. For neurological applications, the researchers are exploring the potential of drugs derived from medicinal mushrooms, including those with psychedelic properties, to treat conditions like depression, anxiety, and other mental health disorders.

News Archive

UFS launches history book

2007-02-02


Attending the launch of the UFS history book were, from the left: Prof Stef Coetzee, Prof Francois Retief, Prof Wynand Mouton, Mr Pieter Cox (Chairperson on Sasol) and Prof Frederick Fourie (Rector and Vice-Chancellor of the UFS). Profs Coetzee, Retief and Mouton are former rectors of the UFS.
UFS launches history book The University of the Free State (UFS) today launched its history book titled, From Grey to Gold, on the Main Campus in Bloemfontein. “The history of the UFS is one of faith, hope, struggle and determination. The book tells a fascinating story that stretches over a 100 years. It is divided into five main phases, which tells about the growth of the UFS from a poor Free State community to a mature university. Interesting stories about student days, sport, rag and hostel activities are included in each phase,” Prof Frederick Fourie, Rector and Vice-Chancellor said during the launch of the book. “One cannot know where you are going if you don’t know where you are coming from. You have a clearer idea of the issues facing an institution if you know the history. A book like this one is also an important source of reference for staff on the campus,” said Prof Fourie. The first research for the book was done from 1999-2003 by Prof Leo Barnard from the Department of History and a team of researchers. They also compiled the first manuscript. During the last three years, Prof Fourie was closely involved with the writing of the final phase and finishing off the history book project. “It was an honour to be so closely involved with the story of the UFS because now I have a better understanding of the institution, its people, its culture and its way of thinking. For any rector of a university, such an understanding of its institution is a requirement,” Prof Fourie said. The book is partly sponsored by Sasol. During the launch of the book, Mr Pieter Cox, Chairperson of Sasol said the company and the UFS have been partners for 57 years. “Both Sasol and the UFS are striving for excellence – Sasol for excellence in technology and the UFS for excellence in education,” said Mr Cox. “It was an easy decision when the UFS approached Sasol for financial support of the history book. Its a formidable piece of work, something Prof Fourie and the UFS can be proud of,” said Mr Cox. The book consists of more than 500 pages with hundreds of photos and a wide range of supplements of office-bearers, awards and achievements (including national and sporting colours). A timeline framework, putting the history of the UFS in context with the history of the Free State, South Africa and of the world, is also included. Besides the supplements, the history book also tells the story of amongst others the establishment of the UFS; the role of its founding fathers; black pioneers of transformation; the establishment and development of academic departments and faculties; student numbers; pioneers and trends in research; academic entrepreneurs; campus issues and campus politics; interesting facts and stories about student life (rag, intervarsity and cheerleaders, sport and the Springboks, hostel traditions); the admission of black students and anguish about race; language and culture; the development of the Main Campus; the Tickey and the Banana and much more. Emphasis is placed on a very high level of quality. “It is not every day that the university becomes hundred years old and the institution will be measured by the quality of the book. We cannot say the UFS is a university of excellence if the book does not reflect that,” Ms Edma Pelzer, Director: Physical Resources and Special Projects said. Ms Pelzer managed the project as part of the last mentioned part of her portfolio. The search for photographs was an important aspect of the book and it was a big task to find photographs and write captions. It took almost a year to translate and prepare the English edition and almost ten months to ensure the accuracy thereof, especially to correctly translate the typical Free State and UFS terminology and naturally to complete the English manuscript’s layout and proofreading. In the mean time the cover pages were designed and in September 2006 the manuscript went into the final print process. The Afrikaans title is: Van Sink tot Sandsteen tot Graniet. The cost of the book is R380 per copy. Those who already ordered the book will soon receive their copy. Orders can be placed by contacting Mr Dawid Kriel at UFS Marketing on 051 401 3409 or on the UFS web site at www.ufs.ac.za. The book is also available at Van Schaik Book Store on the Thakaneng Bridge, UFS Main Campus and at Fascination Books in Mimosa Mall, Bloemfontein. Media release Issued by: Lacea Loader Media Representative Tel: (051) 401-2584 Cell: 083 645 2454 E-mail: loaderl@mail.uovs.ac.za 2 February 2007

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept